Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients
Sun Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC.
(WRAL Tech Wire
Related: Campus Connections
Recent Campus Connections News:
UNC performs longest running shark survey in the U.S.
Professor Frank Schwartz of the UNC Institute of Marine Sciences officially started the shark survey in 1972, although he unofficially began collecting data on sharks...Wednesday August 12, 2020'It's tough': Franklin Street restaurants prepare for uncertain fall sports season
For over 10 years, Kristian Bawcom has owned Four Corners on Franklin Street, one of the many restaurants that Tar Heel fans and students go...Wednesday August 12, 2020A new take on Carolina traditions
The start of the UNC experience for new students has been far from conventional, but Sunday, these students experienced one important tradition when University leaders...Tuesday August 11, 2020First day at Zoom University: UNC students share their atypical FDOC experiences
The first day of class at UNC usually gives campus a bustling, exciting feeling. But, because of the pandemic, the Pit and Polk Place —...Tuesday August 11, 2020